Recent Updates
Recently added Catalysts
PROF Positive Sentiment

Update: Profound Medical’s Scheduled Presentation at the 43rd Annual J.P. Morgan Healthcare Conference Moved Up to 9:00am PT on January 16th

Monday, January 13, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Profound Medical Corp. has announced a change in the timing of its presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The new presentation time is set for 9:00 a.m. Pacific Time on January 16, 2025. This event highlights the company's ongoing efforts in developing incision-free therapies for tissue ablation.
Price reaction · baseline $7.57 (2025-01-10 close) · hit pre-market · clean, no other PROF news in the window
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Profound Medical is actively participating in a major healthcare conference.
  • The presentation time change indicates increased visibility for the company.
  • The company continues to develop innovative medical device therapies.

Full Press Release Details

TORONTO, Jan. 13, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its scheduled presentation time at the 43rd Annual J.P. Morgan Healthcare Conference has been changed to 9:00 a.m. Pacific Time on Thursday, January 16, 2025.

Frequently Asked Questions

What is the new presentation time for Profound Medical?

The new presentation time is 9:00 a.m. Pacific Time on January 16, 2025.

Where is Profound Medical presenting?

Profound Medical is presenting at the 43rd Annual J.P. Morgan Healthcare Conference.

What does Profound Medical specialize in?

Profound Medical develops customizable, incision-free therapies for tissue ablation.

ShareAdd on Google
Tags: PROF Viatris Investor Conferences Healthcare Profound Medical J.P. Morgan Healthcare Conference medical device tissue ablation
Last updated: Jan 13, 2025

Biotech snapshot

Cash runway
$38M liquidity · $4M/mo burn
~10 mo
Medium dilution risk